Cost analysis compares osimertinib plus platinum-pemetrexed with amivantamab plus lazertinib in patients with lung cancer, suggesting a cost advantage for osimertinib.
From a US payer perspective, osimertinib plus platinum-pemetrexed was associated with substantially lower overall costs compared with IV and SC amivantamab plus lazertinib for the 1L treatment of patients with EGFRm locally advanced or metastatic NSCLC.
No takes yet. Share an insight, caveat, or question.
Lopes et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: